Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study

• Ngā kaituhi matua: Joeri W. van Straalen (Author), Sytze de Roock (Author), Gabriella Giancane (Author), Alessandro Consolaro (Author), Marite Rygg (Author), Ellen B. Nordal (Author), Nadina Rubio-Pérez (Author), Marija Jelusic (Author), Jaime De Inocencio (Author), Jelena Vojinovic (Author), Nico M. Wulffraat (Author), Patricia C. J. Bruijning-Verhagen (Author), Nicolino Ruperto (Author), Joost F. Swart (Author), for the Paediatric Rheumatology International Trials Organisation (PRINTO) (Author)
• Hōputu: Pukapuka
• I whakaputaina: BMC, 2022-11-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Abstract Background Etanercept (ETN) and adalimumab (ADA) are considered equally effective biologicals in the treatment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-reported well-being. The objective of this study was to determine whether E...